

Name of Journal: *World Journal of Clinical Oncology*

ESPS Manuscript NO: 20981

Manuscript Type: Editorial

Targeting EZH2 as a promising strategy for cancer treatment

Irene Marchesi, Luigi Bagella

Abstract

Polycomb group (PcG) proteins represent a global silencing system involved in development regulation. In specific, they regulate the transition from proliferation to differentiation, contributing to stem-cell maintenance and inhibiting an inappropriate activation of differentiation programs. Enhancer of Zeste Homolog 2 (EZH2) is the

Match Overview

Match 31 of 31		
1	Internet 432 words crawled on 01-Dec-2015 www.intechopen.com	3%
2	CrossCheck 130 words Marchesi, Irene, and Luigi Bagell. "Role of Enhancer of Zeste Homolog 2 Polycomb Protein and Its Significance ..."	1%
3	CrossCheck 80 words Epigenetics and Cancer, 2013.	1%
4	CrossCheck 57 words Choudhury, S. R., S. Balasubramanian, Y. C. Chew, B. Han, V. E. Marquez, and R. L. Eckert. "(-)-Epigallocatechin gallate (EGCG) as a novel histone deacetylase inhibitor in human breast cancer cells."	<1%
5	CrossCheck 56 words Wang, Wei, Jiang-Jiang Qin, Sukesh Voruganti, Subhasree Nag, Jianwei Zhou, and Ruiwen Zhang. "Polycomb Group Proteins: Molecular Mechanisms and Therapeutic Targets in Cancer."	<1%
6	CrossCheck 49 words Marchesi, Irene, Francesco Paolo Fiorentino, Flavio Rizzolio, Antonio Giordano, and Luigi Bagella. "The ablation of EZH2 in human breast cancer cells induces a transcriptional reprogramming that leads to a more differentiated phenotype."	<1%
7	CrossCheck 48 words McCabe, Michael T., Heidi M. Ott, Gopinath Ganji, Susan	<1%

[PDF] [Targeting EZH2 for Castration Resistant Prostate Cancer Kexin Xu1 ...](#)

www.pcf.org/atf/cf/{7c77d6a2-5859-4d60-af47-132fd0f85892}/Kexin_Xu.pdf

Targeting EZH2 for Castration Resistant Prostate Cancer. Kexin Xu1,2, Han Xu1,3, ... represents a promising strategy for prostate cancer treatment. However, the....

[PDF] [Targeting EZH2 for Castration Resistant Prostate Cancer Kexin Xu1 ...](#)

www.pcf.org/atf/cf/{7c77d6a2-5859-4d60-af47-132fd0f85892}/2014-ABSTRACTS-XU-KEXI

methyltransferase EZH2 is an attractive therapeutic target for cancer1-3. ... represent a promising strategy for prostate cancer treatment, especially for CRPC. AR.

[British Journal of Cancer - The role of EZH2 in tumour progression](#)

www.nature.com/bjc/journal/v106/n2/full/bjc2011551a.html

20 Dec 2011 ... Finally, we will describe cancer therapies that target EZH2 or its a promising strategy for anticancer treatment targeting tumour cells, tumour....

[Ovarian cancer discovery suggests new treatment strategy - Medical ...](#)

www.medicalnewstoday.com/articles/289534.php

17 Feb 2015 ... Researchers have discovered a therapeutic target for ovarian clear cell ... The study explored the possibility of inhibiting EZH2 as a cancer ... The researchers confirmed this might be a promising way forward ... inhibition of EZH2 represents a novel treatment strategy for cancers involving ARID1A mutations.

[Targeting oncogenic ALK: a promising strategy for cancer treatment.](#)

www.ncbi.nlm.nih.gov/pubmed/21474455

Mol Cancer Ther. 2011 Apr.10(4):569-79. doi: 10.1158/1535-7163.MCT-10-0615. Targeting oncogenic ALK: a promising strategy for cancer treatment. Grande....

[Update of research on the role of EZH2 in cancer progression](#)

www.ncbi.nlm.nih.gov/pmc/articles/PMC3622432/

4 Apr 2013 ... Therefore, inhibiting EZH2 expression may be a promising strategy for ... that target EZH2 and could be potentially applied in the treatment of....

[PDF] [PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for ...](#)

www.researchgate.net/profile/Gustavo_Amarante-Mendes/publication/233890695_PRAME

pathway for cancer therapy, such as recombinant TRAIL, agonist antibodies for TRAIL receptors, and adenoviral ... promising histone methyltransferase target for cancer therapy [71]. ... adequate

学术搜索

找到约 1,560 条结果 (用时0.30秒)

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置 指定搜索语言

时间不限

2016以来

2015以来

2012以来

自定义范围...

EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis
[F Crea](#), [L Fornaro](#), [G Bocci](#), [L Sun](#), [WL Farrar](#)... - *Cancer and Metastasis* ..., 2012 - Springer
 ... cy is one of the possible mechanisms of resistance to VEGF- **targeting** agents, such as ... VEGF recep- tor 2 (VEGFR2) activation triggers several kinase-dependent pathways, which in turn ... at hindering multiple pro-angiogenic path- ways by the use of multi-**targeted** tyrosine-kinase ...
 被引用次数: 78 相关文章 所有 10 个版本 引用

按相关性排序

按日期排序

Targeting hypoxia in cancer therapy

[WR Wilson](#), [MP Hay](#) - *Nature Reviews Cancer*, 2011 - nature.com

... initiating cells through HIF1-dependent upregulation of the Polycomb protein **enhancer of zeste** ... Perhaps the most crucial requirement for hypoxia-**targeting strategies** is the development of ... host genomic analyses will revolutionize the matching of hypoxia-**targeted** therapeutics to ...
 被引用次数: 683 相关文章 所有 7 个版本 引用

搜索所有网页

中文网页

简体中文网页

Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin

[CH Li](#), [KF To](#), [JHM Tong](#), [Z Xiao](#), [T Xia](#), [PBS Lai](#)... - *Gastroenterology*, 2013 - Elsevier

... 3 and 4 Recently, it was shown that the gene expression regulator **enhancer of zeste homolog (EZH)2** is ... Lentiviral vector containing either short-hairpin RNA (shRNA) **targeting** EZH2, or the stem loop of miR-218-2 (retrieved from miRBase) was cloned into H1 promoter ...
 被引用次数: 28 相关文章 所有 8 个版本 引用

 包括专利 包含引用

Drug delivery of siRNA therapeutics: potentials and limits of nanosystems

[D Reischl](#), [A Zimmer](#) - *Nanomedicine: Nanotechnology, Biology and* ..., 2009 - Elsevier

... such as sugar modifications (eg, 2'-O-methyl and 2'-deoxy-2'-fluoro (OMe/F ... To achieve cell-specific delivery of siRNA, several **targeting** ligands, such as cell membrane receptors and antibodies, have been successfully explored that ensure **targeted** delivery of ...
 被引用次数: 158 相关文章 所有 5 个版本 引用

[HTML] Regulation of **tumor angiogenesis** by EZH2

[C Lu](#), [HD Han](#), [LS Mangala](#), [R Ali-Fehmi](#), [CS Newton](#)... - *Cancer cell*, 2010 - Elsevier

... Although VEGF-**targeted** therapies are showing promise, new angiogenesis targets are needed to ... **Targeting** the **tumor vasculature** is a particularly attractive **strategy** because of the presumed ... increased expression in **tumor endothelial cells**, we focused on the **enhancer of Zeste**

[全部](#)[新闻](#)[图片](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 21,500 条结果 (用时 0.66 秒)

Google 学术: Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment

EZH2 inhibition: targeting the crossroad of tumor ... - Crea - 被引用次数: 78

Targeting hypoxia in cancer therapy - Wilson - 被引用次数: 683

Enhancer of zeste homolog 2 silences microRNA-218 ... - Li - 被引用次数: 28

The polycomb group protein EZH2 is a novel therapeutic ...

www.ncbi.nlm.nih.gov > ... > PubMed Central (PMC) ▾ 翻译此页

作者: Z Li - 2013 - 被引用次数: 18 - 相关文章

2013年12月7日 - Oral cancer is the sixth most common cancers worldwide with more than 70% ... The enhancer of zeste homolog (EZH2) is a core catalytic subunit of the ... may represent a promising strategy for novel anticancer treatment. ... Additionally, the therapeutic efficiency of EZH2-targeting compounds like DZNep as ...

Targeting self-renewal pathways in cancer stem cells ...

www.nature.com > Journal home > Archive > November 30 2015 - 翻译此页

作者: A Borah - 2015

2015年11月30日 - Current treatment strategies in cancer fail to detect and differentiate the ... the SRPs in CSCs offer a promising target to alter their survival strategies and ... approach against the enhancer of zeste homolog 2 and Oct-4 genes ...

Paper: Novel Leukemia Stem Cell-Targeted Therapy for ...

<https://ash.confex.com/ash/2015/webprogram/Paper81803.html> ▾ 翻译此页

¹Division of Hematological Malignancy, National Cancer Center Research Institute, Tokyo, ... Selective targeting of LSCs is a promising strategy for the prevention and ... Enhancer of zeste homolog 1 and 2 (EZH1/2) is a catalytic component of ...

Novel Therapeutic Approaches for Targeting Tumor